| アブストラクト | Gilteritinib is currently approved for patients with relapsed/refractory AML with FLT3 mutations, based on the positive results of the pivotal ADMIRAL study. In ADMIRAL trial, no increased risk of bleeding was reported, but in the previous dose finding study, a single event of intracranial hemorrhage (ICH) was registered after exposure to subtherapeutic doses of gilteritinib. Here, we report the first case series on five ICHs diagnosed in patients with FLT3-mutated AML, occurred within the first month of exposure to gilteritinib. Our cohort included 24 patients treated in three Italian centers. Most of these ICH cases were non-severe and self-limiting, while one was fatal. This link with ICHs remains in any case uncertain for the presence of active AML. We further reported that an analysis of the post-marketing surveillance data (EudraVigilance) retrieved other 11 cases of ICHs present in the database after gilteritinib treatment. A causality assessment was performed according to the Dx3 method to evaluate the possibility that ICHs might be an actual side effect of gilteritinib. In conclusion, further research is needed to elucidate the potential role of gilteritinib in the pathogenesis of ICHs. |
|---|
| 投稿者 | Perrone, Salvatore; Imperatore, Stefano; Sucato, Giuseppe; Notarianni, Ermanno; Corbingi, Andrea; Andriola, Costanza; Napolitano, Mariasanta; Pulsoni, Alessandro; Molica, Matteo |
|---|
| 組織名 | Department of Hematology, S.M. Goretti Hospital, Polo Universitario Pontino,;"Sapienza," Via A. Canova, 04100, Latina, Italy.;Department of Health Promotion, Mother and Child Care, Internal Medicine and;Medical Specialties (PROMISE), University of Palermo, Palermo, Italy.;Diagnostic and Interventional Unit, "Santa Maria Goretti" Hospital, Via Antonio;Canova, Latina, Italy.;"Sapienza," Via A. Canova, 04100, Latina, Italy. alessandro.pulsoni@uniroma1.it.;Department of Hematology-Oncology, Azienda Ospedaliera Pugliese-Ciaccio,;Catanzaro, Italy. |
|---|
